Results 31 to 40 of about 264,442 (390)
European Heart Journal, 2022 Background The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction.
W. Doehner +11 more
semanticscholar +1 more source
Heart Failure with Reduced Ejection Fraction—Does Sex Matter? [PDF]
Current Heart Failure Reports, 2021 Abstract Purpose of Review There is an increasing recognition of the importance of sex in susceptibility, clinical presentation, and outcomes for heart failure. This review focusses on heart failure with reduced ejection fraction (HFrEF), unravelling differences in biology, clinical and demographic features and ...
Swaraj, Sascha +4 more
openaire +2 more sources
ESC Heart Failure, 2022 Aims In the heart failure (HF) with preserved ejection fraction (HFpEF) PARAGON‐HF trial, sacubitril/valsartan vs. valsartan improved mortality/morbidity in patients with left ventricular ejection fraction (LVEF) below median (57%).
Lars H. Lund +9 more
doaj +1 more source
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]
, 2016 Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva +17 more
core +1 more source
European Heart Journal, 2021 Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with ...
J. Butler +19 more
semanticscholar +1 more source
Heart failure with reduced ejection fraction due topolycythemia vera [PDF]
Oxford Medical Case Reports, 2021 ABSTRACT Polycythemia vera is a rare hematological disorder that can cause heart failure with reduced ejection fraction from chronic micro-vascular ischemia. Appropriately recognizing the underlying cause of cardiomyopathy is essential to decrease morbidity and mortality.
Muhammad Omer Zaman +6 more
openaire +2 more sources
Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]
, 2017 Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz +17 more
core +3 more sources
Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction [PDF]
, 2015 Reduced exercise tolerance is an independent predictor of hospital readmission and mortality in patients with heart failure (HF). Exercise training for HF patients is well established as an adjunct therapy, and there is sufficient evidence to support the
Goh, CY +4 more
core +2 more sources
JAMA cardiology, 2021 Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF).
D. Berg +15 more
semanticscholar +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundWorsening renal function (WRF) is associated with adverse outcomes in patients with heart failure. We investigated the predictors and prognostic value of WRF during admission, in patients with preserved ejection fraction (HFpEF) versus those ...
Jeehoon Kang +20 more
doaj +1 more source